Have a feature idea you'd love to see implemented?
Let us know!
GLYC Glycomimetics Inc
Price (delayed)
$0.32
Market cap
$20.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.62
Enterprise value
$6.51M
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate
Highlights
The debt has dropped by 74% year-on-year and by 42% since the previous quarter
Glycomimetics's equity has plunged by 76% YoY and by 43% from the previous quarter
GLYC's quick ratio has shrunk by 57% YoY and by 35% QoQ
Key stats
What are the main financial stats of GLYC
Market
Valuations
Earnings
Shares outstanding
64.48M
Market cap
$20.63M
Enterprise value
$6.51M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.81
Price to sales (P/S)
2,063.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
650.53
Revenue
$10,000
EBIT
-$39.74M
EBITDA
-$39.09M
Free cash flow
-$35.02M
Per share
Balance sheet
Liquidity
EPS
-$0.62
Free cash flow per share
-$0.54
Book value per share
$0.18
Revenue per share
$0
TBVPS
$0.24
Total assets
$15.7M
Total liabilities
$4.32M
Debt
$262,133
Equity
$11.38M
Working capital
$11.32M
Debt to equity
0.02
Current ratio
3.62
Quick ratio
3.33
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
-390,864.4%
Gross margin
100%
Net margin
-397,350.5%
Operating margin
-422,973.5%
Return on assets
-132.9%
Return on equity
-160.9%
Return on invested capital
N/A
Return on capital employed
-349.3%
Return on sales
-397,350.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLYC stock price
How has the Glycomimetics stock price performed over time
Intraday
-3.03%
1 week
-19.88%
1 month
100%
1 year
-78.67%
YTD
-86.44%
QTD
89.35%
Financial performance
How have Glycomimetics's revenue and profit performed over time
Revenue
$10,000
Gross profit
$10,000
Operating income
-$42.3M
Net income
-$39.74M
Gross margin
100%
Net margin
-397,350.5%
Glycomimetics's operating income has decreased by 4.9% YoY and by 3.5% from the previous quarter
Glycomimetics's net income has decreased by 4.4% YoY
The operating margin has declined by 3.5% since the previous quarter
Growth
What is Glycomimetics's growth rate over time
Valuation
What is Glycomimetics stock price valuation
P/E
N/A
P/B
1.81
P/S
2,063.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
650.53
Glycomimetics's equity has plunged by 76% YoY and by 43% from the previous quarter
GLYC's price to book (P/B) is 42% lower than its last 4 quarters average of 3.1 but 6% higher than its 5-year quarterly average of 1.7
GLYC's P/S is 78% below its last 4 quarters average of 9298.6 and 16% below its 5-year quarterly average of 2454.3
Efficiency
How efficient is Glycomimetics business performance
The ROE has plunged by 118% YoY and by 38% from the previous quarter
Glycomimetics's return on assets has shrunk by 106% YoY and by 33% QoQ
Dividends
What is GLYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLYC.
Financial health
How did Glycomimetics financials performed over time
The total assets has plunged by 70% YoY and by 36% from the previous quarter
GLYC's quick ratio has shrunk by 57% YoY and by 35% QoQ
The debt is 98% smaller than the equity
Glycomimetics's equity has plunged by 76% YoY and by 43% from the previous quarter
The debt has dropped by 74% year-on-year and by 42% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.